Alexandria Venture Investments logo

Alexandria Venture Investments

North America, California, United States, Pasadena

Description

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities, Inc. (ARE), a leading urban office REIT focused on collaborative life science, agrifoodtech, and technology campuses. Leveraging its parent company's extensive real estate and scientific ecosystem, Alexandria Venture Investments provides strategic capital to innovative companies across the life science, agrifoodtech, clean energy, and advanced technology sectors. Their unique position allows them to offer not only financial investment but also access to ARE's vast network, specialized infrastructure, and deep industry expertise, fostering the growth and success of their portfolio companies.

The firm's investment strategy is comprehensive, spanning the entire lifecycle of companies from seed-stage startups to those approaching an IPO. They are known for their long-term partnership approach, often supporting companies through multiple funding rounds. Beyond capital, Alexandria Venture Investments actively assists portfolio companies with critical resources, including access to state-of-the-art laboratory and office space, scientific advisory boards, and opportunities for collaboration within Alexandria's vibrant tenant community. This integrated approach aims to accelerate the development and commercialization of groundbreaking technologies.

Alexandria Venture Investments has established itself as a significant player in the venture capital landscape, demonstrating a robust and consistent investment track record. To date, they have invested over $2.9 billion across more than 800 companies, showcasing their extensive reach and commitment to fostering innovation in their core sectors. Their portfolio includes a diverse range of companies, from novel therapeutic developers and diagnostic innovators to leaders in sustainable agriculture and cutting-edge technology solutions. This deep engagement underscores their role as a crucial enabler of scientific and technological advancement.

Investor Profile

Alexandria Venture Investments has backed more than 280 startups, with 31 new investments in the last 12 months alone. The firm has led 16 rounds, about 6% of its total and boasts 51 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B, Series C rounds (top funding stages).
  • Majority of deals are located in United States, France, Canada.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.
  • Led 2 rounds in the past year.
  • Typical check size: $1M – $20M.

Stage Focus

  • Series A (39%)
  • Series B (26%)
  • Series C (12%)
  • Seed (10%)
  • Series Unknown (5%)
  • Post Ipo Equity (2%)
  • Series D (2%)
  • Convertible Note (2%)
  • Series E (1%)

Country Focus

  • United States (95%)
  • France (2%)
  • Canada (2%)
  • Switzerland (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science
  • Pharmaceutical
  • Biopharma
  • Genetics
  • Oncology
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Alexandria Venture Investments frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 24
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 19
CA
North America, Massachusetts, United States, Boston
Co-Investments: 23
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 31
Casdin Capital
North America, New York, United States, New York
Co-Investments: 29
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 20
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 22
Invus
North America, New York, United States, New York
Co-Investments: 17
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 48
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 21

Which angels does Alexandria Venture Investments often collaborate with?

MC
North America, North Dakota, United States, Fargo
Shared Deals: 1
Shared Deals: 2
JM
North America, United States
Shared Deals: 1
BG
North America, Washington, United States, Seattle
Shared Deals: 3
TA
North America, Massachusetts, United States, Cambridge
Shared Deals: 1
MA
North America, California, United States, San Francisco
Shared Deals: 1
CP
North America, California, United States, San Francisco
Shared Deals: 1
GL
North America, Connecticut, United States, Hartford
Shared Deals: 1
FB
North America, New York, United States, New York
Shared Deals: 2
JB
North America, North Dakota, United States, Fargo
Shared Deals: 1

What are some of recent deals done by Alexandria Venture Investments?

ARTBIO

Cambridge, Massachusetts, United States

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

BiotechnologyHealth CareHospitalMedicalMedical DevicePharmaceutical
Series BJul 29, 2025
Amount Raised: $132,000,000
Dispatch Bio

Philadelphia, Pennsylvania, United States

Dispatch Bio helps create a world where all cancer patients can be cured.

BiotechnologyHealth CareTherapeutics
Series AJul 23, 2025
Amount Raised: $216,000,000
GeneCentric Therapeutics

Durham, North Carolina, United States

GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.

BiotechnologyHealth CareHealth Diagnostics
Series CJun 18, 2025
Amount Raised: $8,000,000
Remedy Plan Therapeutics

Gaithersburg, Maryland, United States

Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.

BiotechnologyHealth DiagnosticsMedicalTherapeutics
Series UnknownMay 13, 2025
Amount Raised: $18,000,000
HAYA Therapeutics

Lausanne, Vaud, Switzerland

HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.

BiotechnologyGeneticsHealth CareMedicalTherapeutics
Series AMay 8, 2025
Amount Raised: $65,000,000
Hoofprint Biome

Raleigh, North Carolina, United States

Hoofprint Biome is a biotechnology company that develops probiotics that improve the sustainability of ruminant livestock production.

Animal FeedBiotechnologyLife ScienceLivestock
Series AApr 29, 2025
Amount Raised: $15,000,000
Solu Therapeutics

Boston, Massachusetts, United States

Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.

BiotechnologyMedicalTherapeutics
Series AApr 9, 2025
Amount Raised: $41,000,000
Neurona Therapeutics

San Francisco, California, United States

Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.

BiotechnologyHealth CareTherapeutics
Series FApr 3, 2025
Amount Raised: $102,000,000
Latigo Biotherapeutics

Thousand Oaks, California, United States

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

BiotechnologyHealth CareMedicalTherapeutics
Series BMar 17, 2025
Amount Raised: $150,000,000
Avalo

Durham, North Carolina, United States

Avalo is a plant biotech company using AI and evolution to make a more sustainable and resilient food system.

AgricultureBiotechnologyMachine Learning
Series AMar 6, 2025
Amount Raised: $11,000,000